Texas Oncology is taking significant steps to address two major challenges in cancer care delivery: financial toxicity and limited clinical trial access in underserved communities. These initiatives aim to bridge critical gaps in cancer care accessibility and research participation.
Tackling Financial Barriers in Cancer Care
Financial toxicity remains a significant obstacle for many cancer patients seeking treatment. To combat this challenge, Texas Oncology has implemented a multi-faceted approach to financial assistance. "We have a team in our pharmacy that coordinates things like rebate cards [and] foundation support," explains Dr. Susan Escudier, medical oncologist and vice president of value-based care and quality programs at Texas Oncology.
The organization leverages various support mechanisms, including foundation assistance programs and pharmaceutical company discounts. Additionally, dedicated social workers help patients navigate government assistance programs and connect them with community resources for transportation and lodging support.
However, Dr. Escudier acknowledges the complexity of the current system: "It's a tough problem because it's a very fragmented safety net." The inconsistency in available support across different pharmaceutical companies adds another layer of complexity to the challenge.
Expanding Clinical Trial Access Beyond Urban Centers
Texas Oncology has made remarkable progress in democratizing clinical trial access by extending research opportunities to rural communities. This expansion represents a significant departure from the traditional concentration of clinical trials in urban academic centers.
"One of the ways we've been able to increase the diversity of our trials is just by having them available in almost all of our clinics," Dr. Escudier notes. "That way, if you're in a rural area, you still have access to research studies that you might think of as being restricted to big urban hospitals or cancer centers."
Community-Specific Engagement Strategies
The organization has adopted a nuanced approach to clinical trial enrollment, recognizing that different communities require tailored engagement strategies. This localized approach takes into account regional and cultural differences across Texas.
"What's successful in a predominantly Spanish-speaking population in the Rio Grande Valley might be different than what's successful in West Texas," Dr. Escudier explains. The organization relies heavily on local physicians and clinic staff's understanding of their communities to develop effective outreach strategies.
This community-centered approach involves engaging with local populations to understand their specific needs and preferences regarding research participation. By meeting patients where they are and incorporating community feedback, Texas Oncology is working to create more inclusive and accessible clinical trial opportunities.
